Ancient Killer Is Rapidly Becoming Resistant to Antibiotics, Warns Study
According to research published in 2022, the bacterium that causes typhoid fever is evolving extensive drug resistance, and is rapidly replacing strains that aren't resistant.
Currently, antibiotics are the only way to effectively treat typhoid, which is caused by the bacterium Salmonella enterica serovar Typhi (S Typhi). Yet over the past three decades, the bacterium's resistance to oral antibiotics has been growing and spreading.
In their study, researchers sequenced the genomes of 3,489 S Typhi strains contracted from 2014 to 2019 in Nepal, Bangladesh, Pakistan, and India, and found a rise in extensively drug-resistant (XDR) Typhi.
XDR Typhi is not only impervious to frontline antibiotics, like ampicillin, chloramphenicol, and trimethoprim/sulfamethoxazole, but it is also growing resistant to newer antibiotics, like fluoroquinolones and third-generation cephalosporins.
Related:
Even worse, these strains are spreading globally at a rapid rate.
While most XDR Typhi cases stem from south Asia, researchers have identified nearly 200 instances of international spread since 1990.
Most strains have been exported to Southeast Asia, as well as East and Southern Africa, but typhoid superbugs have also been found in the United Kingdom, the United States, and Canada.
"The speed at which highly-resistant strains of S Typhi have emerged and spread in recent years is a real cause for concern, and highlights the need to urgently expand prevention measures, particularly in countries at greatest risk," said infectious disease specialist Jason Andrews from Stanford University at the time the results were published.
Scientists have been warning about drug-resistant typhoid for years now. In 2016, the first XDR typhoid strain was identified in Pakistan. By 2019, it had become the dominant genotype in the nation.
Historically, most XDR typhoid strains have been fought with third-generation antimicrobials, like quinolones, cephalosporins, and macrolides.
But by the early 2000s, mutations that confer resistance to quinolones accounted for more than 85 percent of all cases in Bangladesh, India, Pakistan, Nepal, and Singapore. At the same time, cephalosporin resistance was also taking over.
Today, only one oral antibiotic is left: the macrolide, azithromycin. And this medicine might not work for much longer.
The 2022 study found mutations that confer resistance to azithromycin are now also spreading, "threatening the efficacy of all oral antimicrobials for typhoid treatment". While these mutations have not yet been adopted by XDR S Typhi, if they are, we are in serious trouble.
If untreated, up to 20 percent of typhoid cases can be fatal, and today, there are 11 million cases of typhoid a year.
Future outbreaks can be prevented to some extent with typhoid conjugate vaccines, but if access to these shots is not expanded globally, the world could soon have another health crisis on its hands.
"The recent emergence of XDR and azithromycin-resistant S Typhi creates greater urgency for rapidly expanding prevention measures, including use of typhoid conjugate vaccines in typhoid-endemic countries," the authors write.
"Such measures are needed in countries where antimicrobial resistance prevalence among S Typhi isolates is currently high, but given the propensity for international spread, should not be restricted to such settings."
South Asia might be the main hub for typhoid fever, accounting for 70 percent of all cases, but if COVID-19 taught us anything, it is that disease variants in our modern, globalized world are easily spread.
To prevent that from happening, health experts argue nations must expand access to typhoid vaccines and invest in new antibiotic research. One recent study in India, for instance, estimates that if children are vaccinated against typhoid in urban areas, it could prevent up to 36 percent of typhoid cases and deaths.
Pakistan is currently leading the way on this front. It was the first nation in the world to offer routine immunization for typhoid. Health experts argue more nations need to follow suit.
Antibiotic resistance is one of the world's leading causes of death, claiming the lives of more people than HIV/ AIDS or malaria. Where available, vaccines are some of the best tools we have to prevent future catastrophe.
We don't have time to waste.
The study was published in The Lancet Microbe.
An earlier version of this article was published in June 2022.
Nicotine Pouches Poisoning Children at an Alarming Rate in The US
Study Reveals How Long We Need to Walk to Prevent Chronic Back Pain
This Is What Happens to Your Body When You Stop Drinking Alcohol
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Times
a day ago
- New York Times
E.P.A. to Stop Updating Popular Database After Lead Scientist Criticized Trump
The Environmental Protection Agency said it would stop updating research that hundreds of companies use to calculate their greenhouse gas emissions after the agency suspended the database's creator because he had signed a letter criticizing the Trump administration's approach to scientific research. The researcher, Wesley Ingwersen, is leaving the E.P.A. to pursue his work at Stanford University. He was one of 139 E.P.A. employees suspended and investigated by the agency after signing the June letter, which charged that Mr. Trump's policies 'undermine the E.P.A. mission of protecting human health and the environment.' Dr. Ingwersen led work on a statistical model that combines environmental and economic data to calculate the carbon footprints — what experts refer to as emissions factors — of a range of goods and services, from making steel to flying planes to growing apples. The open-source data sets help companies understand the greenhouse gases generated by each step in their supply chains. The database is the third most viewed of more than 281,000 federal data sets on the government's public data repository. An earlier version of the database is among the top 10 most viewed. The data sets will remain publicly available but will not be updated to reflect the current state of the economy, rendering them less useful over time. Dr. Ingwersen will move his work to Stanford through a consortium with two private companies, which has pledged to continue updating the information and making it free to the public. Ten most viewed federal datasets, as of Aug. 7 Source: Want all of The Times? Subscribe.
Yahoo
2 days ago
- Yahoo
BioMendics Launches TAMES-02 Clinical Trial for Innovative Epidermolysis Bullosa Simplex Therapy
BioMendics Launches Pivotal TAMES-02 Clinical Trial to Advance TolaSure™ for EB Simplex Patients ROOTSTOWN, Ohio, August 07, 2025--(BUSINESS WIRE)--BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of TolaSure™, a first-in-class topical therapy for patients with generalized intermediate to severe Epidermolysis Bullosa Simplex (EB Simplex). EB Simplex is a rare, inherited skin disorder that causes painful blistering due to fragile skin, affecting an estimated 30,000 to 50,000 individuals worldwide. With current treatment limited to wound care and infection control, patients and families face a lifelong battle without disease-modifying options. TolaSure, developed by BioMendics, aims to change that reality by targeting the mutant keratins that underlie skin fragility, offering a novel mechanism to reduce blister burden and improve quality of life. The TAMES-02 trial builds on the success of the earlier TAMES-01 study, which demonstrated TolaSure's safety and efficacy in adult patients. Dr. Joyce Teng, Principal Investigator at Stanford University, shared: "Our early studies with TolaSure showed meaningful reduction in blistering, which is incredibly encouraging for the EB Simplex community. Clinical research in rare skin diseases requires collaboration with companies like BioMendics and patient advocacy groups like debra of America to accelerate progress toward transformative therapies. Our shared goal is to bring hope and healing to families who have had so few options for so long." TAMES-02 is being conducted in partnership with Stanford University School of Medicine and Northwestern University Feinberg School of Medicine—two globally recognized leaders in dermatology research. The trial will evaluate TolaSure in patients aged 4 and older and includes a 2-month double-blind, placebo-controlled phase, followed by a 2-month open-label phase where all participants receive TolaSure, and a 6-month follow-up. Importantly, the trial allows patients to treat plantar (foot) blistering—a major source of pain and disability for those living with EB Simplex. Dr. Amy Paller, Principal Investigator at Northwestern University, added: "TAMES-02 is a vital next step. The collaboration with BioMendics and Stanford enables us to rigorously evaluate this therapy and, hopefully, bring real progress to patients who have had limited options for far too long." "We're really excited to be able to cover travel cost to bring patients in from all over the United States and internationally," said Dr. Aleesha McCormick Senior clinical research scientist at BioMendics. "EB Simplex patients don't all live close to an Academic Medical Center like Stanford and Northwestern and our goal is to help as many patients be able to participate in the study as possible. Our study design also lets us recruit slightly less severe patients that may not have flared enough to be eligible for other clinical studies." "Our mission is to bring meaningful therapies to patients living with rare diseases like EB Simplex—conditions that have been overlooked for too long," said Dr. Karen M. McGuire, CEO and Founder of BioMendics. "With TolaSure, we're targeting the root cause of blistering by reinforcing fragile keratinocytes. The TAMES-02 trial is a critical step toward proving safety and efficacy. If successful, we'll seek strategic partnerships to help accelerate development and deliver this treatment to patients as quickly as possible. We also see strong potential for TolaSure in other rare keratin disorders such as pachyonychia congenita and epidermolytic ichthyosis." TAMES-02 reflects BioMendics' ongoing commitment to developing innovative, targeted treatments for rare skin disorders and is currently open for patient enrollment. About BioMendics: For more information about BioMendics please visit our website ( BioMendics is proud to be a REDIzone company at Northeast Ohio Medical University (NEOMED). The REDIzone (Research, Entrepreneurship, Discovery, and Innovation Zone) supports local life science and biomedical entrepreneurs by providing access to NEOMED's resources, expertise, and connections to the region's innovation ecosystem. This partnership has been instrumental in advancing TolaSure from research to clinical development. View source version on Contacts To learn more or inquire about participation, visit or contact the study sites below: Stanford University Dermatology Dr. Joyce Teng (Principal Investigator)Contact: Thomas Buschbacher – tbusch@ Questions about participant rights: 1-866-680-2906 Northwestern University Dermatology Dr. Amy Paller (Principal Investigator)Contact: Dr. Lydia Rabbaa Khabbaz – Questions about participant rights: 312-503-7110 BioMendics, LLC Dr. Karen M. McGuire, CEO & Founder – kmcguire@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
BioMendics Launches TAMES-02 Clinical Trial for Innovative Epidermolysis Bullosa Simplex Therapy
BioMendics Launches Pivotal TAMES-02 Clinical Trial to Advance TolaSure™ for EB Simplex Patients ROOTSTOWN, Ohio, August 07, 2025--(BUSINESS WIRE)--BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of TolaSure™, a first-in-class topical therapy for patients with generalized intermediate to severe Epidermolysis Bullosa Simplex (EB Simplex). EB Simplex is a rare, inherited skin disorder that causes painful blistering due to fragile skin, affecting an estimated 30,000 to 50,000 individuals worldwide. With current treatment limited to wound care and infection control, patients and families face a lifelong battle without disease-modifying options. TolaSure, developed by BioMendics, aims to change that reality by targeting the mutant keratins that underlie skin fragility, offering a novel mechanism to reduce blister burden and improve quality of life. The TAMES-02 trial builds on the success of the earlier TAMES-01 study, which demonstrated TolaSure's safety and efficacy in adult patients. Dr. Joyce Teng, Principal Investigator at Stanford University, shared: "Our early studies with TolaSure showed meaningful reduction in blistering, which is incredibly encouraging for the EB Simplex community. Clinical research in rare skin diseases requires collaboration with companies like BioMendics and patient advocacy groups like debra of America to accelerate progress toward transformative therapies. Our shared goal is to bring hope and healing to families who have had so few options for so long." TAMES-02 is being conducted in partnership with Stanford University School of Medicine and Northwestern University Feinberg School of Medicine—two globally recognized leaders in dermatology research. The trial will evaluate TolaSure in patients aged 4 and older and includes a 2-month double-blind, placebo-controlled phase, followed by a 2-month open-label phase where all participants receive TolaSure, and a 6-month follow-up. Importantly, the trial allows patients to treat plantar (foot) blistering—a major source of pain and disability for those living with EB Simplex. Dr. Amy Paller, Principal Investigator at Northwestern University, added: "TAMES-02 is a vital next step. The collaboration with BioMendics and Stanford enables us to rigorously evaluate this therapy and, hopefully, bring real progress to patients who have had limited options for far too long." "We're really excited to be able to cover travel cost to bring patients in from all over the United States and internationally," said Dr. Aleesha McCormick Senior clinical research scientist at BioMendics. "EB Simplex patients don't all live close to an Academic Medical Center like Stanford and Northwestern and our goal is to help as many patients be able to participate in the study as possible. Our study design also lets us recruit slightly less severe patients that may not have flared enough to be eligible for other clinical studies." "Our mission is to bring meaningful therapies to patients living with rare diseases like EB Simplex—conditions that have been overlooked for too long," said Dr. Karen M. McGuire, CEO and Founder of BioMendics. "With TolaSure, we're targeting the root cause of blistering by reinforcing fragile keratinocytes. The TAMES-02 trial is a critical step toward proving safety and efficacy. If successful, we'll seek strategic partnerships to help accelerate development and deliver this treatment to patients as quickly as possible. We also see strong potential for TolaSure in other rare keratin disorders such as pachyonychia congenita and epidermolytic ichthyosis." TAMES-02 reflects BioMendics' ongoing commitment to developing innovative, targeted treatments for rare skin disorders and is currently open for patient enrollment. About BioMendics: For more information about BioMendics please visit our website ( BioMendics is proud to be a REDIzone company at Northeast Ohio Medical University (NEOMED). The REDIzone (Research, Entrepreneurship, Discovery, and Innovation Zone) supports local life science and biomedical entrepreneurs by providing access to NEOMED's resources, expertise, and connections to the region's innovation ecosystem. This partnership has been instrumental in advancing TolaSure from research to clinical development. View source version on Contacts To learn more or inquire about participation, visit or contact the study sites below: Stanford University Dermatology Dr. Joyce Teng (Principal Investigator)Contact: Thomas Buschbacher – tbusch@ Questions about participant rights: 1-866-680-2906 Northwestern University Dermatology Dr. Amy Paller (Principal Investigator)Contact: Dr. Lydia Rabbaa Khabbaz – Questions about participant rights: 312-503-7110 BioMendics, LLC Dr. Karen M. McGuire, CEO & Founder – kmcguire@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data